AI for Early Identification of Breast Cancer – Efficient and Accurate Diagnosis

By Michael Awood

September 15, 2023

Breast cancer is the second leading cause of cancer death in women. Early identification can ease this to ensure early access to treatment. Developed nations have vast mammography screening programs, but interpreting the images is still hard. The accuracy of cancer detection varies widely among experts, and the potential for improvement is significant. False positives can lead to patient anxiety, unnecessary follow-up, and invasive diagnostic procedures. Sometimes screening cannot identify cancers until they are more advanced and less amenable to treatment.

Artificial Intelligence (AI) can overcome this challenge. Studies show it can outperform human experts in many medical image analysis tasks. This leads us to evaluate AI’s potential to augment the early identification process of breast cancer through high-quality images.

Researchers recently tested a new AI system that predicts breast cancer using large datasets from the UK and the USA. The system outperformed radiologists in daily predictions, according to the researchers. They confirmed these observations with an independently conducted reader study. The system could generalize across different screening populations and settings without additional training data.

The AI system might reduce the workload involved in the double-reading process used in the UK while preserving the standard of care. The system could also provide automated, immediate feedback in the screening setting. This technology can sort cases at the risk level, making it possible to screen efficiently even with a limited workforce.

Overall, the AI was better than radiologists at identifying breast cancer. These results held across two large datasets that represent different screening populations and practices. However, the optimal use of the AI system within clinical workflows remains to be determined.

Cover image taken from the journal article. 

Reference url

Recent Posts

EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles

By João L. Carapinha

March 26, 2026

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...